Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
265 Leser
Artikel bewerten:
(1)

Applied Science, Inc.: Community Blood Center of the Ozarks Chooses the HemoFlow 500 and HemoVue Cloud Service to Upgrade Its Whole Blood Collection Operations

Finanznachrichten News

GRASS VALLEY, CA / ACCESSWIRE / July 10, 2024 / Applied Science (ASI), the worldwide leader in whole blood collection products and services, today announced that Community Blood Center of the Ozarks (CBCO) has purchased ASI's next-generation device, the HemoFlow 500, and HemoVue, its recently introduced cloud-based service that works with HemoFlow devices to provide real-time operational data and analytics that significantly improve blood collection and related processes.

HemoFlow 500 blood scale and mixer

HemoFlow 500 blood scale and mixer

Established in 1995, Community Blood Center of the Ozarks is the exclusive provider of blood and blood products to over 40 hospitals in a 41-county area comprising Southwest Missouri, Northwest Arkansas, and Southeast Kansas, as well as the United States military, as part of a national effort to sustain our troops. A longstanding HemoFlow customer, CBCO is upgrading its fleet with 100 state-of-the-art HemoFlow 500xs devices, taking advantage of HemoFlow's advanced software features for remote configuration and real-time monitoring.

"Applied Science is a long-time trusted partner, and the next-generation HemoFlow 500 is the obvious choice for CBCO," said Anthony Roberts, Executive Director of the Community Blood Center of the Ozarks. "Applied Science has always provided CBCO with superb service and support, so extending our relationship is the natural next step. Additionally, the organization sees high value in the new software platform HemoVue and its ability to perform remote configurations and real-time staff/site monitoring."

The 500 Series devices, weighing in at a mere 3.5 lbs., are the lightest in the industry. With a battery life that supports up to 230 draws per charge, these devices outperform any other blood mixer and scale device on the market. Their advanced features, including a large touch-screen display, integrated barcode scanner, onboard collection record storage, and wireless connectivity, streamline the donation process. This not only maximizes collection efficiency but also provides a paperless, automated whole-blood collection system. The system removes the friction of manual data entry, optimizes each donation, eliminates process errors, reduces waste, enhances profitability, and allows phlebotomists to focus on caring for donors, making a significant impact on the donation process.

"Our market-leading customer base has come to expect quality, reliability, and innovation from Applied Science's HemoFlow products and how they help improve efficiency, reduce errors, and better manage inventory and donations, among their many other benefits," said Jonathan Morgan, President and CEO of Applied Science. "Our business is all about harnessing the power of healthcare workflow automation and data to make the delivery of care easier, smarter, more efficient, and frictionless for providers of this vital, life-saving service."

About Applied Science

Applied Science provides workflow automation and data integration platforms for transfusion medicine and chronic care management. Through its HemoFlow brand, Applied Science is the industry-leading provider of solutions for customers all over the world, from the American Red Cross to the UK's National Health Service. By extending its expertise throughout underserved healthcare communities, the Company is empowering health systems to manage outcomes remotely and efficiently for their patients with chronic conditions. Through advanced devices, services, informatics, and data tools that automate healthcare workflow processes, Applied Science's customers capture healthcare data that enable actionable intelligence. For more information, please visit applied-science.com.

Contact Information

Hillary Odgers
V.P. - Finance and Administration
hillary_odgers@applied-science.com
530.273.8299 X.210

Related Images

HemoFlow 500 blood scale and mixer

HemoFlow 500 blood scale and mixer

HemoVue, providing real-time operational data and analytics

HemoVue, providing real-time operational data and analytics

SOURCE: Applied Science, Inc.

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.